Association of metformin use with risk and prognosis of esophageal cancer in patients with diabetes: A systematic review and meta-analysis
- VernacularTitle:二甲双胍与糖尿病患者食管癌发生风险及预后相关性的系统评价与 Meta 分析
- Author:
Yanming WU
1
;
Yan WANG
1
;
Jialong LI
1
;
Wenpeng SONG
1
;
Guowei CHE
1
Author Information
1. Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China
- Publication Type:Journal Article
- Keywords:
Metformin;
diabetes;
esophageal cancer;
disease risk;
prognosis;
systematic review/meta-analysis
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2022;29(02):179-185
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the relationship between metformin use and the risk and prognosis of esophageal cancer in patients with diabetes. Methods The PubMed, Web of Science, EMbase, VIP, WanFang and CNKI databases were searched by computer to identify relevant studies from inception to August 21, 2021. Newcastle-Ottawa scale (NOS) was used to evaluate research quality. The STATA 12.0 software was used to conduct the statistical analysis. Results A total of 14 studies involving 5 605 218 participants were included finally. NOS of all researches were≥6 points. The pooled results indicated that metformin use could decrease the risk of esophageal cancer in diabetics (OR=0.84, 95%CI 0.71-1.00, P=0.045), and could also prolong the overall survival of diabetics with esophageal cancer (HR=0.89, 95%CI 0.80-0.99, P=0.025). Conclusion Metformin use can not only decrease the risk of esophageal cancer in patients with diabetes, but also improve the prognosis of diabetics with esophageal cancer significantly. However, more prospective high-quality studies are still needed to verify the conclusion.
